These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 33188747)
1. Intestinal protozoa and helminths in ulcerative colitis and the influence of anti-parasitic therapy on the course of the disease. Toychiev A; Navruzov B; Pazylova D; Davis N; Badalova N; Osipova S Acta Trop; 2021 Jan; 213():105755. PubMed ID: 33188747 [TBL] [Abstract][Full Text] [Related]
2. Intestinal helminths and protozoan infections in patients with colorectal cancer: prevalence and possible association with cancer pathogenesis. Toychiev A; Abdujapparov S; Imamov A; Navruzov B; Davis N; Badalova N; Osipova S Parasitol Res; 2018 Dec; 117(12):3715-3723. PubMed ID: 30220046 [TBL] [Abstract][Full Text] [Related]
3. Six ulcerative colitis patients with refractory symptoms co-infective with Blastocystis hominis in China. Tai WP; Hu PJ; Wu J; Lin XC Parasitol Res; 2011 May; 108(5):1207-10. PubMed ID: 21104272 [TBL] [Abstract][Full Text] [Related]
4. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies. Sandborn WJ; Hanauer S; Lichtenstein GR; Safdi M; Edeline M; Scott Harris M Aliment Pharmacol Ther; 2011 Oct; 34(7):747-56. PubMed ID: 21848857 [TBL] [Abstract][Full Text] [Related]
6. Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis. Yamamoto T; Shimoyama T; Matsumoto K Aliment Pharmacol Ther; 2015 Sep; 42(5):549-58. PubMed ID: 26140337 [TBL] [Abstract][Full Text] [Related]
7. Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Active Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study. Sun J; Yuan Y Adv Ther; 2016 Mar; 33(3):400-9. PubMed ID: 26898569 [TBL] [Abstract][Full Text] [Related]
8. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542 [TBL] [Abstract][Full Text] [Related]
9. Low prevalence of Blastocystis sp. in active ulcerative colitis patients. Rossen NG; Bart A; Verhaar N; van Nood E; Kootte R; de Groot PF; D'Haens GR; Ponsioen CY; van Gool T Eur J Clin Microbiol Infect Dis; 2015 May; 34(5):1039-44. PubMed ID: 25680316 [TBL] [Abstract][Full Text] [Related]
10. Intestinal protozoa infections among patients with ulcerative colitis: prevalence and impact on clinical disease course. Yamamoto-Furusho JK; Torijano-Carrera E Digestion; 2010; 82(1):18-23. PubMed ID: 20145404 [TBL] [Abstract][Full Text] [Related]
11. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life. Probert CS; Dignass AU; Lindgren S; Oudkerk Pool M; Marteau P J Crohns Colitis; 2014 Mar; 8(3):200-7. PubMed ID: 24012063 [TBL] [Abstract][Full Text] [Related]
12. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Vecchi M; Meucci G; Gionchetti P; Beltrami M; Di Maurizio P; Beretta L; Ganio E; Usai P; Campieri M; Fornaciari G; de Franchis R Aliment Pharmacol Ther; 2001 Feb; 15(2):251-6. PubMed ID: 11148445 [TBL] [Abstract][Full Text] [Related]
13. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Kruis W; Brandes JW; Schreiber S; Theuer D; Krakamp B; Schütz E; Otto P; Lorenz-Mayer H; Ewe K; Judmaier G Aliment Pharmacol Ther; 1998 Aug; 12(8):707-15. PubMed ID: 9726382 [TBL] [Abstract][Full Text] [Related]
14. 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial. Gross V; Bunganic I; Belousova EA; Mikhailova TL; Kupcinskas L; Kiudelis G; Tulassay Z; Gabalec L; Dorofeyev AE; Derova J; Dilger K; Greinwald R; Mueller R; J Crohns Colitis; 2011 Apr; 5(2):129-38. PubMed ID: 21453882 [TBL] [Abstract][Full Text] [Related]
15. Effect of nitazoxanide in persistent diarrhea and enteritis associated with Blastocystis hominis. Rossignol JF; Kabil SM; Said M; Samir H; Younis AM Clin Gastroenterol Hepatol; 2005 Oct; 3(10):987-91. PubMed ID: 16234044 [TBL] [Abstract][Full Text] [Related]
16. Mesalazine dose modification based on faecal calprotectin levels in patients with ulcerative colitis in clinical remission. Piñero G; Mañosa M; Calafat M; Vayreda E; Cañete F; Puig M; Domènech E Gastroenterol Hepatol; 2024; 47(6):612-619. PubMed ID: 37806344 [TBL] [Abstract][Full Text] [Related]
17. Intestinal parasite infections in a rural community of Rio de Janeiro (Brazil): Prevalence and genetic diversity of Blastocystis subtypes. Barbosa CV; Barreto MM; Andrade RJ; Sodré F; d'Avila-Levy CM; Peralta JM; Igreja RP; de Macedo HW; Santos HLC PLoS One; 2018; 13(3):e0193860. PubMed ID: 29522552 [TBL] [Abstract][Full Text] [Related]
18. Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Remission Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study. Sun J; Yuan Y Adv Ther; 2016 Mar; 33(3):410-22. PubMed ID: 26905266 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of intestinal protozoa infection among school-aged children on Pemba Island, Tanzania, and effect of single-dose albendazole, nitazoxanide and albendazole-nitazoxanide. Speich B; Marti H; Ame SM; Ali SM; Bogoch II; Utzinger J; Albonico M; Keiser J Parasit Vectors; 2013 Jan; 6():3. PubMed ID: 23289920 [TBL] [Abstract][Full Text] [Related]
20. Effects of mesalazine combined with bifid triple viable on intestinal flora, immunoglobulin and levels of cal, MMP-9, and MPO in feces of patients with ulcerative colitis. Jiang XE; Yang SM; Zhou XJ; Zhang Y Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):935-942. PubMed ID: 32017001 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]